Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Alvotech

Market Cap 1.24B 1.09B 1.01B 941M 1.76B 117B 1.8B 12.09B 4.68B 57.6B 4.65B 4.55B 200B P/E 2026 *
9.25x
P/E 2027 * 8.47x
Enterprise Value 2.34B 2.06B 1.9B 1.78B 3.33B 220B 3.39B 22.81B 8.84B 109B 8.78B 8.59B 378B EV / Sales 2026 *
3.54x
EV / Sales 2027 * 3.01x
Free-Float
41.72%
Yield 2026 *
-
Yield 2027 * -
Current month-60.55%
Current year-60.55%
5 years 3.64
Extreme 3.645
10.44
10 years 3.64
Extreme 3.645
11.62
Manager TitleAgeSince
Chief Executive Officer 55 28/02/2026
Director of Finance/CFO 48 09/07/2025
Chief Tech/Sci/R&D Officer - 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2018
Director/Board Member 64 31/12/2018
Director/Board Member 58 31/12/2018
Date Insider Type Main position Quantity % Market Cap.
20/09/20OthersCompany 218,750 3.8889%
15/09/20OtherCompany 0 0%
15/09/20OtherCompany 6,468,750 115.0000%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.39% - - 1.24B
+2.56%+7.12%-7.30%+1.26% 44.45B
+0.15%+7.61%+324.11%+582.63% 36.04B
+0.36%+5.50%+3.87%+53.88% 30.7B
+8.37%+8.76%+17.05%-13.19% 28.59B
+7.60%-1.03%+14.05%+20.82% 23.01B
-0.24%+2.97% - - 14.82B
+8.30%+12.19%+62.65%+127.80% 13.52B
+2.73%+6.86%+12.60%+18.45% 12.98B
+0.70%+2.97%+93.04%+95.70% 12.56B
Average +3.00%+2.88%+65.01%+110.92% 24.07B
Weighted average by Cap. +3.11%+3.11%+71.66%+128.71%

Financials

2026 *2027 *
Net sales 661M 582M 537M 502M 940M 62.28B 958M 6.45B 2.5B 30.72B 2.48B 2.43B 107B 784M 690M 637M 595M 1.12B 73.89B 1.14B 7.65B 2.96B 36.45B 2.94B 2.88B 127B
Net income 165M 145M 134M 125M 235M 15.55B 239M 1.61B 624M 7.67B 619M 606M 26.69B 134M 118M 109M 102M 191M 12.64B 194M 1.31B 507M 6.23B 503M 492M 21.69B
Net Debt 1.1B 968M 892M 835M 1.56B 104B 1.59B 10.73B 4.15B 51.1B 4.13B 4.04B 178B 1.12B 986M 909M 850M 1.59B 106B 1.62B 10.92B 4.23B 52.05B 4.2B 4.11B 181B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
24/06/26 US$3.700 0.00% 785,248
23/06/26 US$3.700 +1.37% 787,900
22/06/26 US$3.650 -6.89% 1,012,041
18/06/26 US$3.920 +0.13% 1,080,458
17/06/26 US$3.915 +1.16% 882,239
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
3.700USD
Average target price
13.83USD
Spread / Average Target
+273.87%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!